Efficacy of Pirarubicin dominated chemotherapy regimen for patients with non-Hodgkin's lymphoma

Objective To evaluate the efficacy and safety of Pirarubicin(THP) dominated regimen(CTOP) in the treatment of non-Hodgkin's lymphoma(NHL).Methods A total of 59 NHL patients who received CTOP regimen were divided into two groups according to the dose of THP.The low dose group was composed of 26 patients treated with THP 23-35mg/m2,and the high dose group consisted of 33 patients receiving THP 40-75mg/m2.The other medication was the same.All patients received 2-8 course of treatment(mean 4).The efficacy and side effects were evaluated.Results Complete remission was achieved in 13 cases and partial remission in 3 cases in the low dose group;while complete remission in 20 cases and partial remission in 6 cases in the high dose group,with the overall response rate being 61.5% and 78.8% respectively.Bone marrow suppression,Grade 3 and 4 neutropenia occurred in 30.8% patients of the low dose group and 27.3% patients of the high dose group.No cardiotoxicity was seen in a short term,and there were respectively 2 patients who suffered from hepatic toxicity in both groups.Conclusion CTOP regimen is effective and safe in the treatment of NHL.A standard dosage of THP is preferred if possible.